



## **NEW! Surrey Heartlands Joint Formulary and Prescribing Advisory Database (PAD)**

On Thursday 22<sup>nd</sup> May the Surrey PAD will be replaced by the new Joint Formulary & PAD platform.

The current PAD site will automatically re-direct you to the new platform.

Users of the Surrey PAD will find that the search function is very similar to the current PAD - entering a drug name or condition will produce a list of search results.

A search will take you to the Formulary page instead of the PAD.

The PAD pages will be accessible from the Formulary page for users that wish to see more information.

*See following slides for screen shots and further information*





# Key features – Home page

Search here using a drug name, condition name or commonly used term

Or select a letter of the alphabet to view a list of drugs in alphabetical order (system uses international non-proprietary names / generic names)

## Search

Search terms include drug names, indications, brand names and keywords.

Please enter a search term and click the 'Search' button.

Search

Reset

A-Z of Drugs :

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

## Quick Links

Please select from the links below to explore this site.

- Guidelines
- Non-Clinical Profiles
- Traffic Light Status Key
- Icon Key
- User Guide
- News
- Contact Us

Welcome to the Formulary and PAD

Show

Contact Us if you have a problem, have spotted a potential error or wish to provide feedback

## News

No records returned.

## Latest Additions (24)

Show

This space will be used to provide important updates. For example, safety alerts, stock shortages, launch of new guidelines etc

Identify the newest content by showing the “Latest Additions”. Particularly useful for a quick view of the latest APC or DTC decisions





# Key features – Formulary page

Search

apixaban

Search

Reset

A-Z of Drugs :

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

## Search Results : apixaban (Apixaban - Atrial fibrillation)

Records returned : 9 (on 06 May 2025 at 11:56:24).

[Return to search results for 'apixaban'.](#)

☒ Show Icon and Status Keys

Drug	Indication	Status	Restrictions/Comments	Formulary Status	Links
Apixaban	Atrial fibrillation	Green Formulations : • Tablets	★ Preferred	Primary Care ASPH RSFT SASH SABP	Guidelines SPC
Warfarin sodium	Atrial fibrillation	Green Formulations : • Tablets		Primary Care ASPH RSFT SASH SABP	Guidelines SPC NICE
Dabigatran etexilate	Atrial fibrillation	Green (see narrative) Formulations : • Capsules		Primary Care ASPH RSFT SASH SABP	Guidelines SPC NICE
Edoxaban	Atrial fibrillation	Formulations : • Tablets		Primary Care ASPH RSFT SASH SABP	Guidelines SPC NICE
Rivaroxaban	Atrial fibrillation	Green (see narrative) Formulations : • Tablets		Primary Care ASPH RSFT SASH SABP	Guidelines SPC NICE
Dronedaron hydrochloride	Atrial fibrillation	Red Formulations : • Tablets		Primary Care ASPH RSFT SASH SABP	Guidelines SPC
Acenocoumarol	Atrial fibrillation	Non Formulary Formulations : • Tablets		Primary Care ASPH RSFT SASH SABP	Guidelines SPC NFD1
Aspirin	Atrial fibrillation	Non Formulary Formulations : • Not Specified		Primary Care ASPH RSFT SASH SABP	Guidelines SPC NFD1

From the formulary page you can also conduct searches

The drug you have searched for will appear at the top of the results list, followed by other drugs for the same indication. You will also see the Traffic Light Status, formulation and any notes relating to place in therapy, restrictions etc

IMPORTANT – some drugs are NOT on formulary at all Trusts / Primary Care. A ✓ or ✗ has been applied to each organisation to denote their formulary status.

Click on a drug name to go to the PAD page which contains additional information e.g. explanation of committee decisions, committee papers, patient resources, safety information etc

Links to guidelines, the SPC and NICE have been provided (where available)





# Key features – PAD page

## Apixaban - Atrial fibrillation

You are here : [Home](#) > [Formulary Search](#) > [Apixaban - Atrial fibrillation](#)

I agree that in using this database, this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

### Status 1

Formulations :

Green

• Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC NICE

Restrictions / Comments :

★ Preferred

### Documentation

Guidelines (Local)	<a href="#">Atrial Fibrillation Management - Secondary Care Pathway - February 2018</a>
Guidelines (Local)	<a href="#">Atrial Fibrillation Management - Primary Care Pathway - February 2018</a>
Guidelines (Local)	<a href="#">Dual antiplatelet-anticoagulant therapy - Aide memoire for managing Hospital Requests</a>
Guidelines (Local)	<a href="#">Oral Anticoagulant selection tool in Atrial Fibrillation - Jun 24.pdf</a>
Guidelines (National)	<a href="#">NICE Clinical guideline [CG180] : Atrial fibrillation: management</a>
NICE Technology Appraisal	<a href="#">NICE TA275 Apixaban for nonvalvular atrial fibrillation</a>
Safety Information	<a href="#">Thrombosis risk in patients with antiphospholipid syndrome - Safety alert - May 2019</a>
Evidence Review	<a href="#">Atrial Fibrillation Management - Evidence Review - September 2014</a>
Patient resource	<a href="#">Atrial Fibrillation - NICE Patient Decision Aid - Jun 2014</a>
Patient resource	<a href="#">Starting Anticoagulation video for patients - Wessex AHSN</a>
Patient resource	<a href="#">Atrial Fibrillation and Stroke Patient Information - East of England PAC resource - Mar 16</a>
Patient resource	<a href="#">Direct Oral Anticoagulants (DOACs) - Patient Information Leaflet - Aug 2019</a>
Education material (for healthcare personnel)	<a href="#">Oral anticoagulant Patient Counselling Checklist for DOACs - Sep 2019</a>
Education material (for healthcare personnel)	<a href="#">Assessing Renal Function for Drug Dose Adjustments in Primary Care - May 2020.pdf</a>
Information	<a href="#">ORBIT Bleed risk scoring tool for anticoagulation in AF - March 2022.pdf</a>
Information	<a href="#">Calculating Creatinine Clearance for DOACs - April 2020</a>

### PAD Profile

Chemical Substance :	Apixaban
Indication :	Atrial fibrillation
Group Name :	
Keywords :	SPAF, Stroke prevention in AF, NOACs, DOACs, new oral anticoagulant, AF, non-vitamin K oral anticoagulants, anticoagulant alert cards, anticoagulant cards, mdcALC, Cockcroft-Gault, creatinine clearance, renal disease, renal impairment, prescribing in older people, polypharmacy, medicines safety, bleed, risk, ORBIT
Brand Names Include :	Eliquis
Important Information :	
Latest Additions Date From :	
Latest Additions Date To :	
Guidelines :	<a href="#">Atrial fibrillation</a>
Supporting Documents :	16

Documents that have been agreed at APC or Trust DTC will be available here

Quick navigation is available to:  
Other indications that are treated by the selected drug and  
Other drugs that are used to treat the selected indication

### Other Indications

Below are listed other indications that Apixaban is used to treat.

- Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
- VTE prophylaxis

### Other Drugs

Below are listed other drugs that are used to treat Atrial fibrillation.

- Acenocoumarol
- Aspirin
- Dabigatran etexilate
- Dronedrone hydrochloride
- Edoxaban
- Phenindione
- Rivaroxaban
- Warfarin sodium

A brief description of the APC / DTC decision can be found here

### Committee Recommendations (5)

#### 07 Feb 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the updated Surrey Heartlands Oral Anticoagulant selection tool in Atrial Fibrillation.

**Apixaban is now the recommended 1st-line DOAC** in accordance with the updated NHSE Commissioning Recommendations.

Apixaban is available generically and is the most cost-effective DOAC.

Refer to the Oral Anticoagulation Selection Tool for full guidance.

#### 02 Mar 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed the use of an ORBIT-bleed risk scoring tool when considering or reviewing anticoagulant treatment in Atrial Fibrillation (AF).





## Other points to note

- Not all drugs / therapeutic areas will have been uploaded to the new platform before launch. A list of outstanding sections will be provided and updated on the front page of the new platform
- Users are asked to use the “Contact Us” feature (accessible from the Home page) to let us know if any content appears to be incorrect, does not work as expected or if they think anything is missing (this feature is not to be used for raising clinical enquiries)
- Your Pharmacy / Medicines Optimisation Team colleagues will be able to assist you with navigation queries
- A webinar is been planned for Wednesday 11<sup>th</sup> June to provide a demonstration of the new platform and its useful features. More information will follow.

